Celldex at ASCO 2015 in Chicago

There’s always something new happening at Celldex! Come check out our latest activities.


Dr. Reardon Discusses the ReACT Study
Dr. David Reardon (Dana-Farber Cancer Center, Harvard Medical School), lead investigator of the ReACT study, discusses the results of the study via Targeted Oncology at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO).


About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.


Our Pipeline